問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Obstetrics & Gynecology

Taipei Veterans General Hospital

更新時間：2023-09-19

劉芝谷
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

23Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉芝谷

List

32Cases

2020-08-01 - 2023-08-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
19Sites

Not yet recruiting8Sites

Recruiting1Sites

Terminated9Sites

2020-08-01 - 2028-06-30

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-11-01 - 2030-05-18

Phase III

Active
A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

  • Condition/Disease

    Epithelial Ovarian Cancer

  • Test Drug

    注射用凍晶粉末 靜脈輸注液 輸注液 輸注液 濃縮粉劑 輸注液

Participate Sites
9Sites

Recruiting9Sites

2023-08-01 - 2028-03-15

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2026-01-16 - 2033-12-31

Phase III

Active
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOT-ov85/GOG-3102)

  • Condition/Disease

    Ovarian Neoplasms Ovarian Cancer

  • Test Drug

    MK-2870 艾法施®/MVASI®

Participate Sites
5Sites

Recruiting5Sites

2024-02-12 - 2028-11-18

Phase II/III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2025-02-01 - 2033-12-31

Phase III

Active
A phase 3, randomized, open-label, multicenter trial was conducted in patients with platinum-sensitive recurrent ovarian cancer to evaluate the efficacy and safety of sacituzumab tirumotecan (MK-2870) maintenance therapy with or without bevacizumab compared to standard care after second-line platinum-based doublet chemotherapy (TroFuse-022/ENGOT-ov84/GOG-3103).

  • Condition/Disease

    Part 1: (1) Adverse events (AEs) (2) Discontinuation of trial treatment due to AEs Part 2: (1) PFS: Time from randomization to the first recorded disease progression or death from any cause, whichever occurs first.

  • Test Drug

    Dexamethasone MK-2870 MVASI

Participate Sites
5Sites

Recruiting5Sites

2025-07-15 - 2030-12-31

Phase II

Active
A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

  • Condition/Disease

    Malignant Neoplasm

  • Test Drug

    錠劑 錠劑 注射劑 錠劑 注射劑 錠劑

Participate Sites
3Sites

Recruiting3Sites

2025-09-01 - 2029-12-31

Not yet recruiting
A Phase 2, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540A in Healthy Females 16 to 26 Years of Age

  • Condition/Disease

    Healthy

  • Test Drug

    注射劑 注射劑

Participate Sites
6Sites

Recruiting6Sites

2025-03-01 - 2032-01-31

Phase III

Active
A phase 3, open-label, multicenter, randomized trial comparing trastuzumab deruxtecan plus bevacizumab versus bevacizumab alone as first-line maintenance therapy for HER2-positive ovarian cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144-O/GOG-3112/APGOT-OV13).

  • Condition/Disease

    Compare the efficacy of T-DXd plus bevacizumab (Group A) versus bevacizumab monotherapy (Group B) in the HER2 IHC 3+/2+ population, as assessed by BICR for progression-free survival (PFS).

  • Test Drug

    Trastuzumab Deruxtecan (T-DXd、DS-8201a)

Participate Sites
7Sites

Recruiting7Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB